Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to IP protections under Bayh/Dole.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Duration: April 1, 2009
to
March 31, 2019
General Issues: Health Issues , Medicare/Medicaid , Copyright/Patent/Trademark , Foreign Relations , Pharmacy , Budget/Appropriations , Taxation/Internal Revenue Code , Miscellaneous Tariff Bills
Spending: about $2,610,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: U.S. Senate, House of Representatives
Related Foreign Entities:
Astellas Pharma, Inc. (Tokyo, JPN); contribution to lobbying: $0; ownership 99%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jonathon Jones Chief of Staff, Senator Carper
Legislative Director, Senator Carper
Chief of Staff, Sen. Tom Carper (2001-2006); Legislative Director, Sen. Tom Carper (2001)
John Michael Gonzalez Chief of Staff, Rep. Melissa Bean
Chief of Staff, Rep. Chris Bell
Chief of Staff, Rep. Melissa Bean (2005-2009); Chief of Staff, Rep. Chris Bell (2003-2005)
Sheila Murphy Legislative Director, Senator Klobuchar
Legislative Director, Rep. Richard Durbin
Legislative Director, Senator Bob Kerrey
Legislative Director, Senator Ben Nelson
Legislative Director, Senator Tom Carper
LD and Interim COS, Senator Amy Klobuchar
Subcomm. on Fed. Financial Mgmnt
Senior Foreign Policy Advisor, Senator Daschle
Sean Richardson Chief of Staff, Senator Klobuchar
Chief of Staff, Senator Amy Klobuchar
Chief of Staff, Rep. Patrick Kennedy
Dpty Staff Dir., Dem Tech and Com. Committee
Policy Advisor, Rep. Dick Gephardt
Staff Assistant, Rep. Dick Gephardt
Corey Malmgren Sen. Bill Nelson, Deputy Legislative Director & Health Counsel (2015-2018); Rep. Sandy Levin, Legislative Counsel (2013-2015), Legislative Correspondent, Staff Assistant (2008-2009); House Committee on Ways and Means, Legal Clerk/Intern (2010)
Bryant Hall Staff Director, Sen. Veterans Affairs Committee (2003-2004); Legislative Director, Sen. Bob Graham (1999-2003)
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Tiber Creek Group lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 12.
Original Filing: 301548669.xml
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to IP protections under Bayh/Dole.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Tiber Creek Group lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 18.
Original Filing: 301528346.xml
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to IP protections under Bayh/Dole.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Tiber Creek Group lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 15, 2023.
Original Filing: 301500918.xml
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). Issues related to women's health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Tiber Creek Group lobbied for Astellas Pharma US, Inc. , earning $20,000. The report was filed on July 19, 2023.
Original Filing: 301483876.xml
Lobbying Issues
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
2nd Quarter, 2023
Tiber Creek Group filed a lobbying registration on July 12, 2023 to represent Astellas Pharma US, Inc., effective June 1, 2023.
Original Filing: 301475095.xml
Issue(s) they said they’d lobby about: Value of Prescription Drugs; Issues related to Bayh-Dole Act (PL96-517); Issues related to pharmaceutical supply chain, COVID-19 response and health appropriations; Issues related to Medicare Part D policies, including non-interference and rebate policy issues; Drug costs and pricing policy issues; Transparency policy issues; Biopharmaceutical innovation and patent policy issues. .
1st Quarter, 2019
Peck Madigan Jones terminated an engagement in which they represented Astellas Pharma US, Inc. on April 22, 2019.
Original Filing: 301036670.xml
Lobbying Issues
Issues relating to drug pricing, march-in rights under Bayh-Dole Act P.L. 96-517, and transparency. Issues related to the Medicare Part D pricing reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 1 - Title IV - Campaign Finance Transparency
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 18, 2019.
Original Filing: 301009244.xml
Lobbying Issues
Issues relating to drug pricing, march-in rights under Bayh-Dole Act P.L. 96-517 and transparency. Issues related to the Medicare Part D coverage gap
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 2482 - Foreign Agents Registration Amendment Act of 2018; S. 2039 - Disclosing Foreign Influence Act; HR 4170 - Disclosing Foreign Influence Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 22, 2018.
Original Filing: 300996968.xml
Lobbying Issues
Issues relating to drug pricing, march-in rights under Bayh-Dole Act P.L. 96-517 and transparency. Issues related to the Medicare Part D coverage gap
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 2482 - Foreign Agents Registration Amendment Act of 2018; S. 2039 - Disclosing Foreign Influence Act; HR 4170 - Disclosing Foreign Influence Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300975075.xml
Lobbying Issues
issues relating to drug pricing, march-in rights under Bayh-Dole Act P.L. 96-517 and transparency. S.1519, the National Defense Authorization Act for 2018, Section 892, Rights in technical data related to medical research. HR 2819 - National Defense Authorization Act (FY18), Amendment 342, Rep. Doggett
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 2482 - Foreign Agents Registration Amendment Act of 2018; S. 2039 - Disclosing Foreign Influence Act; HR 4170 - Disclosing Foreign Influence Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300954331.xml
Lobbying Issues
issues relating to drug pricing, march-in rights under Bayh-Dole Act P.L. 96-517 and transparency. S.1519, the National Defense Authorization Act for 2018, Section 892, Rights in technical data related to medical research. HR 2819 - National Defense Authorization Act (FY18), Amendment 342, Rep. Doggett
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 2482 - Foreign Agents Registration Amendment Act of 2018; S. 2039 - Disclosing Foreign Influence Act; HR 4170 - Disclosing Foreign Influence Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 22, 2018.
Original Filing: 300933780.xml
Lobbying Issues
issues relating to drug pricing, march-in rights under Bayh-Dole Act P.L. 96-517 and transparency. S.1519, the National Defense Authorization Act for 2018, Section 892, Rights in technical data related to medical research. HR 2819 - National Defense Authorization Act (FY18), Amendment 342, Rep. Doggett
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 20, 2017.
Original Filing: 300911384.xml
Lobbying Issues
issues relating to drug pricing, march-in rights under Bayh-Dole Act P.L. 96-517 and transparency. S.1519, the National Defense Authorization Act for 2018, Section 892, Rights in technical data related to medical research. HR 2819 - National Defense Authorization Act (FY18), Amendment 342, Rep. Doggett
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 20, 2017.
Original Filing: 300892097.xml
Lobbying Issues
issues relating to drug pricing, march-in rights under Bayh-Dole Act P.L. 96-517 and transparency.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 20, 2017.
Original Filing: 300872198.xml
Lobbying Issues
issues relating to drug pricing, march-in rights under Bayh-Dole Act P.L. 96-517
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 23, 2017.
Original Filing: 300854649.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517). Issues related to drug pricing.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
Peck Madigan Jones amended a lobbying report for representation of Astellas Pharma US, Inc. in Q32016 on Nov. 13, 2017.
Original Filing: 300919100.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
Peck Madigan Jones amended a lobbying report for representation of Astellas Pharma US, Inc. in Q32016 on Jan. 24, 2017.
Original Filing: 300858840.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 20, 2016.
Original Filing: 300834808.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 20, 2016.
Original Filing: 300816474.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 20, 2016.
Original Filing: 300801475.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 20, 2016.
Original Filing: 300779015.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 20, 2015.
Original Filing: 300762568.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 20, 2015.
Original Filing: 300744938.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $70,000. The report was filed on April 20, 2015.
Original Filing: 300727406.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 20, 2015.
Original Filing: 300705521.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 20, 2014.
Original Filing: 300686027.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 21, 2014.
Original Filing: 300667324.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 21, 2014.
Original Filing: 300646416.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to drug safety. Issues related to CMS Outpatient Prospective Payment System (OPPS) rule.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 21, 2014.
Original Filing: 300622922.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to drug safety. Issues related to CMS Outpatient Prospective Payment System (OPPS) rule.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Track and trace drug verification. H.R. 3204, Drug Quality and Security Act. S. 959, Pharmaceutical Quality, Security, and
Accountability Act. S. 957, Drug Supply Chain Security Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.J. Res. 59, Continuing Appropriations Resolution, 2014 and budget deal. The sequester as it relates to FDA user fees.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 21, 2013.
Original Filing: 300604107.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to drug safety.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 22, 2013.
Original Filing: 300582820.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to drug safety.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 22, 2013.
Original Filing: 300561918.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to drug safety.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Peck Madigan Jones lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 22, 2013.
Original Filing: 300539013.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to drug safety.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Peck Madigan Jones (formerly Peck, Madigan, Jones & Stewart, Inc.) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 22, 2012.
Original Filing: 300520364.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to drug safety. S. 1734, Generating Antibiotic Incentives Now Act of 2011. S. 3187, the Food and Drug Administration Safety and Innovation Act, now Public Law No: 112-144.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 20, 2012.
Original Filing: 300495356.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to drug safety. S. 1734, Generating Antibiotic Incentives Now Act of 2011. S. 3187, the Food and Drug Administration Safety and Innovation Act, now Public Law No: 112-144.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 20, 2012.
Original Filing: 300474863.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to the supply of medical isotopes (S. 99, the American Medical Isotopes Production Act). Issues related to reauthorization of the Prescription Drug User Fee Act. Issues related to cancer research and treatment. Issues related to drug safety. S. 1734, Generating Antibiotic Incentives Now Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the pharmaceutical sales fee for Medicare Part B. Issues related to the renewal of the R&D tax credit.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to S.23/H.R. 1249, America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2011
In Q4, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 20, 2012.
Original Filing: 300449643.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to the supply of medical isotopes (S. 99, the American Medical Isotopes Production Act). Issues related to reauthorization of the Prescription Drug User Fee Act. Issues related to cancer research and treatment. Issues related to drug safety.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the pharmaceutical sales fee for Medicare Part B. Issues related to the renewal of the R&D tax credit.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to S.23/H.R. 1249, America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2011
In Q3, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 20, 2011.
Original Filing: 300424768.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to the supply of medical isotopes (S. 99, the American Medical Isotopes Production Act). Issues related to reauthorization of the Prescription Drug User Fee Act. Issues related to cancer research and treatment. Issues related to drug safety.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the pharmaceutical sales fee for Medicare Part B. Issues related to the renewal of the R&D tax credit.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to S.23/H.R. 1249, America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2011
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 20, 2011.
Original Filing: 300401403.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to the supply of medical isotopes (S. 99, the American Medical Isotopes Production Act). Issues related to reauthorization of the Prescription Drug User Fee Act. Issues related to cancer research and treatment. Issues related to drug safety.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the pharmaceutical sales fee. Issues related to the renewal of the R&D tax credit.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to S.23/H.R. 1249, America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
In Q1, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 20, 2011.
Original Filing: 300376096.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics. Issues related to the supply of medical isotopes (S. 99, the American Medical Isotopes Production Act). Issues related to reauthorization of the Prescription Drug User Fee Act. Issues related to cancer research and treatment. Issues related to drug safety.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the pharmaceutical sales fee. Issues related to the renewal of the R&D tax credit.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to S.23/H.R. 1249, America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 20, 2011.
Original Filing: 300352611.xml
Lobbying Issues
H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. Incentives for companies to develop anti-biotics/anti-infectives. H.R. 6331, Generating Antibiotic Incentives Now Act of 2010. Issues pertaining to community and hospital acquired infections (HAC). 340b program. Biosimilars. H.R. 2400, the Strategies to Address Antimicrobial Resistance Act. H.R.4213, American Jobs and Closing Tax Loopholes Act of 2010: 340b provisions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. Issues pertaining to community and hospital acquired infections (HAC).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2753, a bill to suspend temporarily the suspension of duty on RSD 1235.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
3rd Quarter, 2010
In Q3, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 20, 2010.
Original Filing: 300327237.xml
Lobbying Issues
H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. Incentives for companies to develop anti-biotics/anti-infectives. H.R. 6331, Generating Antibiotic Incentives Now Act of 2010. Issues pertaining to community and hospital acquired infections (HAC). 340b program. Biosimilars. H.R. 2400, the Strategies to Address Antimicrobial Resistance Act. H.R.4213, American Jobs and Closing Tax Loopholes Act of 2010: 340b provisions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. Issues pertaining to community and hospital acquired infections (HAC).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2753, a bill to suspend temporarily the suspension of duty on RSD 1235.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
2nd Quarter, 2010
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 20, 2010.
Original Filing: 300297724.xml
Lobbying Issues
H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Incentives for companies to develop anti-biotics/anti-infectives with FDA priority reveiw voucher. Issues pertaining to community and hospital acquired infections (HAC). 340b program. Biosimilars. H.R. 2400, the Strategies to Address Antimicrobial Resistance Act. H.R.4213, American Jobs and Closing Tax Loopholes Act of 2010: 340b provisions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Issues pertaining to community and hospital acquired infections (HAC).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2753, a bill to suspend temporarily the suspension of duty on RSD 1235.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
1st Quarter, 2010
In Q1, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 20, 2010.
Original Filing: 300270810.xml
Lobbying Issues
H.R.3590, Patient Protection and Affordable Care Act. H.R.4872, Health Care and Education Reconciliation Act of 2010. H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Incentives for companies to develop anti-biotics/anti-infectives with FDA priority reveiw voucher. Issues pertaining to community and hospital acquired infections (HAC). 340b program. Biosimilars.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4872, Health Care and Education Reconciliation Act of 2010; H.R. 3962, Affordable Health Care for America Act; and H.R. 3590, Patient Protection and Affordable Care Act. H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Issues pertaining to community and hospital acquired infections (HAC).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2753, a bill to suspend temporarily the suspension of duty on RSD 1235.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
4th Quarter, 2009
In Q4, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 20, 2010.
Original Filing: 300247836.xml
Lobbying Issues
Americas Healthy Future Act of 2009. S. 1679, Affordable Health Choices Act. H.R. 3200, America's Affordable Health Choices Act of 2009. H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Incentives for companies to develop anti-biotics/anti-infectives with FDA priority reveiw voucher. Issues pertaining to community and hospital acquired infections (HAC). 340b program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Americas Healthy Future Act of 2009. S. 1679, Affordable Health Choices Act. H.R. 3200, America's Affordable Health Choices Act of 2009. H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Issues pertaining to community and hospital acquired infections (HAC).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 20, 2009.
Original Filing: 300218904.xml
Lobbying Issues
Americas Healthy Future Act of 2009. S. 1679, Affordable Health Choices Act. H.R. 3200, America's Affordable Health Choices Act of 2009. H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Incentives for companies to develop anti-biotics/anti-infectives with FDA priority reveiw voucher. Issues pertaining to community and hospital acquired infections (HAC). 340b program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Americas Healthy Future Act of 2009. S. 1679, Affordable Health Choices Act. H.R. 3200, America's Affordable Health Choices Act of 2009. H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Issues pertaining to community and hospital acquired infections (HAC).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, Peck, Madigan, Jones & Stewart, Inc. lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 20, 2009.
Original Filing: 300188357.xml
Lobbying Issues
Develop. of health care legislation in Sen. Finance Committee. Affordable Health Choices Act. House Tri-Committee draft proposal. H.R. 1458/S. 565, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009. H.R. 574/S. 254, Medicare Home Infusion Therapy Coverage Act of 2009. Incentives for companies to develop anti-biotics/anti-infectives with FDA priority reveiw voucher. Issues pertaining to community and hospital acquired infections (HAC).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Medicaid
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...